Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

education programme

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Amgen hoping to topple Takeda’s $2bn a year drug

Does ‘trust leadership’ feature in your strategy?

Pharma companies wanting to be more patient-focused will need to develop their people skills

Sanofi reception

Sanofi’s Lantus follow-up nears European approval

CHMP backing for Toujeo follows hot on the heels of its US approval by the FDA

- PMLiVE

Greater Manchester to control its share of the NHS budget

The north-west English region accounts for 5% of the country's health spending

EU flag

Jinarc backed for European approval in rare kidney disease

Positive opinion for Otsuka comes just before rare disease awareness day

- PMLiVE

UCB boosted by core medicines growth

Firm’s new chief executive 'excited' by his company’s next batch of medicines

- PMLiVE

Sovaldi-Daklinza combo cures hep C in co-infected HIV patients

Phase III trial of BMS and Gilead antivirals cured 97% of patients

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

- PMLiVE

Bayer’s Eylea cleared for wider use in Europe

Macular oedema treatment reached €759m in sales last year

- PMLiVE

Sanofi joins WHO-backed diabetes mHealth programme

Becomessole pharma partner for Be Healthy, Be Mobile's diabetes arm

- PMLiVE

Russian innovation at the crossroads

Despite improvements, investors face rising risks

- PMLiVE

2015: A year of promise and connectivity

How could technology impact healthcare in this year and what will be the key trends to follow?

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links